Literature DB >> 22303516

Ovarian cancer spheroids use myosin-generated force to clear the mesothelium.

Marcin P Iwanicki1, Rachel A Davidowitz, Mei Rosa Ng, Achim Besser, Taru Muranen, Melissa Merritt, Gaudenz Danuser, Tan A Ince, Tan Ince, Joan S Brugge.   

Abstract

Dissemination of ovarian tumors involves the implantation of cancer spheroids into the mesothelial monolayer on the walls of peritoneal and pleural cavity organs. Biopsies of tumors attached to peritoneal organs show that mesothelial cells are not present under tumor masses. We have developed a live, image-based in vitro model in which interactions between tumor spheroids and mesothelial cells can be monitored in real time to provide spatial and temporal understanding of mesothelial clearance. Here we provide evidence that ovarian cancer spheroids utilize integrin- and talin- dependent activation of myosin and traction force to promote mesothelial cells displacement from underneath a tumor cell spheroid. These results suggest that ovarian tumor cell clusters gain access to the sub-mesothelial environment by exerting force on the mesothelial cells lining target organs, driving migration and clearance of the mesothelial cells.

Entities:  

Keywords:  force; integrins; mesothelium; myosin; ovarian cancer

Mesh:

Substances:

Year:  2011        PMID: 22303516      PMCID: PMC3269166          DOI: 10.1158/2159-8274.CD-11-0010

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  38 in total

1.  In vivo inhibition of CD44 limits intra-abdominal spread of a human ovarian cancer xenograft in nude mice: a novel role for CD44 in the process of peritoneal implantation.

Authors:  T Strobel; L Swanson; S A Cannistra
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

2.  Ovarian cancer development and metastasis.

Authors:  Ernst Lengyel
Journal:  Am J Pathol       Date:  2010-07-22       Impact factor: 4.307

3.  Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

Authors:  Kenjiro Sawada; Anirban K Mitra; A Reza Radjabi; Vinay Bhaskar; Emily O Kistner; Maria Tretiakova; Sujatha Jagadeeswaran; Anthony Montag; Amy Becker; Hilary A Kenny; Marcus E Peter; Vanitha Ramakrishnan; S Diane Yamada; Ernst Lengyel
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

4.  Morphogenesis of peritoneal metastasis in human gastric cancer.

Authors:  Y Kiyasu; S Kaneshima; S Koga
Journal:  Cancer Res       Date:  1981-03       Impact factor: 12.701

5.  The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Authors:  Hilary A Kenny; Swayamjot Kaur; Lisa M Coussens; Ernst Lengyel
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Antioxidant and oncogene rescue of metabolic defects caused by loss of matrix attachment.

Authors:  Zachary T Schafer; Alexandra R Grassian; Loling Song; Zhenyang Jiang; Zachary Gerhart-Hines; Hanna Y Irie; Sizhen Gao; Pere Puigserver; Joan S Brugge
Journal:  Nature       Date:  2009-08-19       Impact factor: 49.962

7.  Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H.

Authors:  S A Cannistra; G S Kansas; J Niloff; B DeFranzo; Y Kim; C Ottensmeier
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

8.  Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

Authors:  Tan A Ince; Andrea L Richardson; George W Bell; Maki Saitoh; Samuel Godar; Antoine E Karnoub; James D Iglehart; Robert A Weinberg
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  Talin depletion reveals independence of initial cell spreading from integrin activation and traction.

Authors:  Xian Zhang; Guoying Jiang; Yunfei Cai; Susan J Monkley; David R Critchley; Michael P Sheetz
Journal:  Nat Cell Biol       Date:  2008-09       Impact factor: 28.824

10.  Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction.

Authors:  R M Heath; D G Jayne; R O'Leary; E E Morrison; P J Guillou
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

View more
  144 in total

1.  Rethinking ovarian cancer: recommendations for improving outcomes.

Authors:  Sebastian Vaughan; Jermaine I Coward; Robert C Bast; Andy Berchuck; Jonathan S Berek; James D Brenton; George Coukos; Christopher C Crum; Ronny Drapkin; Dariush Etemadmoghadam; Michael Friedlander; Hani Gabra; Stan B Kaye; Chris J Lord; Ernst Lengyel; Douglas A Levine; Iain A McNeish; Usha Menon; Gordon B Mills; Kenneth P Nephew; Amit M Oza; Anil K Sood; Euan A Stronach; Henning Walczak; David D Bowtell; Frances R Balkwill
Journal:  Nat Rev Cancer       Date:  2011-09-23       Impact factor: 60.716

Review 2.  Tumor metastasis: molecular insights and evolving paradigms.

Authors:  Scott Valastyan; Robert A Weinberg
Journal:  Cell       Date:  2011-10-14       Impact factor: 41.582

3.  Sirtuin-3 (SIRT3) and the Hallmarks of Cancer.

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Eric Verdin; Yvonne L Kapila
Journal:  Genes Cancer       Date:  2013-03

Review 4.  Metastasis Organotropism: Redefining the Congenial Soil.

Authors:  Yang Gao; Igor Bado; Hai Wang; Weijie Zhang; Jeffrey M Rosen; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2019-05-06       Impact factor: 12.270

Review 5.  Epithelial ovarian cancer experimental models.

Authors:  E Lengyel; J E Burdette; H A Kenny; D Matei; J Pilrose; P Haluska; K P Nephew; D B Hales; M S Stack
Journal:  Oncogene       Date:  2013-08-12       Impact factor: 9.867

6.  The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer.

Authors:  Hilary A Kenny; Kristin M Nieman; Anirban K Mitra; Ernst Lengyel
Journal:  Cancer Discov       Date:  2011-07       Impact factor: 39.397

7.  Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance.

Authors:  Rachel A Davidowitz; Laura M Selfors; Marcin P Iwanicki; Kevin M Elias; Alison Karst; Huiying Piao; Tan A Ince; Michael G Drage; Judy Dering; Gottfried E Konecny; Ursula Matulonis; Gordon B Mills; Dennis J Slamon; Ronny Drapkin; Joan S Brugge
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

8.  Comparative Proteomics of Ovarian Cancer Aggregate Formation Reveals an Increased Expression of Calcium-activated Chloride Channel Regulator 1 (CLCA1).

Authors:  Natasha Musrap; Alessandra Tuccitto; George S Karagiannis; Punit Saraon; Ihor Batruch; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2015-05-24       Impact factor: 5.157

9.  Ovarian cancer: Driving force.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2011-07-14       Impact factor: 60.716

10.  Combination of AKT inhibition with autophagy blockade effectively reduces ascites-derived ovarian cancer cell viability.

Authors:  Rohann J M Correa; Yudith Ramos Valdes; Teresa M Peart; Elena N Fazio; Monique Bertrand; Jacob McGee; Michel Préfontaine; Akira Sugimoto; Gabriel E DiMattia; Trevor G Shepherd
Journal:  Carcinogenesis       Date:  2014-02-22       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.